A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

        1 2 3 | Last   [Sort alphabetically]   [Restore default list]

  Subjects -> PHARMACY AND PHARMACOLOGY (Total: 575 journals)
Showing 1 - 200 of 253 Journals sorted by number of followers
Nature Reviews Drug Discovery     Full-text available via subscription   (Followers: 332)
International Journal of Drug Policy     Hybrid Journal   (Followers: 254)
Journal of Clinical Oncology     Hybrid Journal   (Followers: 242)
Journal of Medicinal Chemistry     Hybrid Journal   (Followers: 157)
Journal of Pharmaceutical Sciences     Hybrid Journal   (Followers: 155)
Drugs     Full-text available via subscription   (Followers: 146)
Advanced Drug Delivery Reviews     Hybrid Journal   (Followers: 98)
Pharmaceutical Research     Hybrid Journal   (Followers: 94)
European Journal of Pharmaceutical Sciences     Hybrid Journal   (Followers: 86)
Drug Safety     Full-text available via subscription   (Followers: 83)
Annals of Pharmacotherapy     Hybrid Journal   (Followers: 56)
Biomaterials     Hybrid Journal   (Followers: 54)
Clinical Pharmacology & Therapeutics     Hybrid Journal   (Followers: 44)
Regulatory Toxicology and Pharmacology     Hybrid Journal   (Followers: 42)
Journal of Controlled Release     Hybrid Journal   (Followers: 38)
Annual Review of Pharmacology and Toxicology     Full-text available via subscription   (Followers: 38)
International Journal of Pharmaceutics     Hybrid Journal   (Followers: 37)
Clinical Therapeutics     Hybrid Journal   (Followers: 34)
European Journal of Pharmaceutics and Biopharmaceutics     Hybrid Journal   (Followers: 34)
Pharmacoepidemiology and Drug Safety     Hybrid Journal   (Followers: 33)
British Journal of Clinical Pharmacology     Hybrid Journal   (Followers: 32)
Journal of Pharmacy and Pharmacology     Full-text available via subscription   (Followers: 31)
Drug Development and Industrial Pharmacy     Hybrid Journal   (Followers: 29)
PharmacoEconomics     Full-text available via subscription   (Followers: 27)
Clinical Pharmacokinetics     Full-text available via subscription   (Followers: 27)
AAPS Journal     Hybrid Journal   (Followers: 26)
Critical Reviews in Toxicology     Hybrid Journal   (Followers: 25)
Journal of Clinical Psychopharmacology     Hybrid Journal   (Followers: 24)
International Journal of Pharmacy Practice     Full-text available via subscription   (Followers: 24)
Toxicology and Applied Pharmacology     Hybrid Journal   (Followers: 24)
Chemical Research in Toxicology     Hybrid Journal   (Followers: 22)
Journal of Pharmacokinetics and Pharmacodynamics     Hybrid Journal   (Followers: 22)
Journal of Pain & Palliative Care Pharmacotherapy     Hybrid Journal   (Followers: 21)
Trends in Pharmacological Sciences     Full-text available via subscription   (Followers: 20)
Journal of Applied Toxicology     Hybrid Journal   (Followers: 19)
Journal of Clinical Pharmacology     Hybrid Journal   (Followers: 19)
Pharmaceutical Development and Technology     Hybrid Journal   (Followers: 19)
American Journal of Cardiovascular Drugs     Hybrid Journal   (Followers: 19)
Clinical Trials     Hybrid Journal   (Followers: 18)
Toxicology     Hybrid Journal   (Followers: 18)
Journal of Pharmaceutical and Biomedical Analysis     Hybrid Journal   (Followers: 18)
Clinical Toxicology     Hybrid Journal   (Followers: 18)
International Journal of Toxicology     Hybrid Journal   (Followers: 17)
Critical Reviews in Clinical Laboratory Sciences     Hybrid Journal   (Followers: 16)
Journal of Clinical Pharmacy and Therapeutics     Hybrid Journal   (Followers: 16)
Journal of Natural Products     Hybrid Journal   (Followers: 16)
Pharmaceutical Statistics     Hybrid Journal   (Followers: 15)
Toxicology Letters     Hybrid Journal   (Followers: 15)
Journal of Pharmacy Practice     Hybrid Journal   (Followers: 15)
Psychopharmacology     Hybrid Journal   (Followers: 15)
Basic & Clinical Pharmacology & Toxicology     Hybrid Journal   (Followers: 14)
Cardiovascular Drugs and Therapy     Hybrid Journal   (Followers: 14)
European Journal of Clinical Pharmacology     Hybrid Journal   (Followers: 14)
Current Medicinal Chemistry     Hybrid Journal   (Followers: 13)
American Journal of Therapeutics     Hybrid Journal   (Followers: 13)
Drug and Chemical Toxicology     Hybrid Journal   (Followers: 13)
Journal of the American Pharmacists Association     Full-text available via subscription   (Followers: 13)
Clinical Research and Regulatory Affairs     Hybrid Journal   (Followers: 12)
Seminars in Hematology     Hybrid Journal   (Followers: 12)
Drug Discovery Today: Technologies     Full-text available via subscription   (Followers: 12)
Current Pharmaceutical Design     Hybrid Journal   (Followers: 12)
Journal of Oncology Pharmacy Practice     Hybrid Journal   (Followers: 12)
Journal of Psychopharmacology     Hybrid Journal   (Followers: 11)
Biopharmaceutics and Drug Disposition     Hybrid Journal   (Followers: 11)
Toxicology in Vitro     Hybrid Journal   (Followers: 11)
Drug Development Research     Hybrid Journal   (Followers: 11)
Drug Metabolism and Disposition     Hybrid Journal   (Followers: 11)
Seminars in Oncology Nursing     Full-text available via subscription   (Followers: 10)
Biochemical Pharmacology     Hybrid Journal   (Followers: 10)
Journal of Separation Science     Hybrid Journal   (Followers: 10)
CNS Drugs     Full-text available via subscription   (Followers: 10)
Current Pharmaceutical Biotechnology     Hybrid Journal   (Followers: 10)
Journal of Medical Marketing     Hybrid Journal   (Followers: 10)
Drugs & Aging     Full-text available via subscription   (Followers: 10)
European Neuropsychopharmacology     Hybrid Journal   (Followers: 9)
Food Additives & Contaminants Part A     Hybrid Journal   (Followers: 9)
Journal of Pharmacology and Experimental Therapeutics     Hybrid Journal   (Followers: 9)
Environmental Toxicology and Pharmacology     Hybrid Journal   (Followers: 9)
Medicinal Chemistry     Hybrid Journal   (Followers: 9)
Biometrical Journal     Hybrid Journal   (Followers: 9)
Drugs & Therapy Perspectives     Full-text available via subscription   (Followers: 9)
Prescriber     Hybrid Journal   (Followers: 9)
ChemMedChem     Hybrid Journal   (Followers: 9)
Current Opinion in Pharmacology     Hybrid Journal   (Followers: 9)
European Journal of Pharmacology     Hybrid Journal   (Followers: 8)
Inhalation Toxicology     Hybrid Journal   (Followers: 8)
Antiviral Research     Hybrid Journal   (Followers: 8)
Drug Metabolism Reviews     Hybrid Journal   (Followers: 8)
Progress in Neuro-Psychopharmacology and Biological Psychiatry     Hybrid Journal   (Followers: 8)
Human & Experimental Toxicology     Hybrid Journal   (Followers: 8)
Drug Delivery     Open Access   (Followers: 8)
BioDrugs     Full-text available via subscription   (Followers: 8)
Frontiers in Drug Design & Discovery     Hybrid Journal   (Followers: 8)
Expert Review of Pharmacoeconomics & Outcomes Research     Full-text available via subscription   (Followers: 8)
Experimental and Clinical Psychopharmacology     Full-text available via subscription   (Followers: 7)
Toxicology Mechanisms and Methods     Hybrid Journal   (Followers: 7)
Journal of Pharmacological and Toxicological Methods     Hybrid Journal   (Followers: 7)
Clinical and Experimental Pharmacology and Physiology     Hybrid Journal   (Followers: 7)
Scandinavian Journal of Clinical and Laboratory Investigation     Hybrid Journal   (Followers: 7)
Epilepsy Research     Hybrid Journal   (Followers: 7)
Clinical Drug Investigation     Full-text available via subscription   (Followers: 7)
Journal of Veterinary Pharmacology and Therapeutics     Hybrid Journal   (Followers: 6)
Toxicology and Industrial Health     Hybrid Journal   (Followers: 6)
Skin Pharmacology and Physiology     Full-text available via subscription   (Followers: 6)
Journal of Cardiovascular Pharmacology     Hybrid Journal   (Followers: 6)
AAPS PharmSciTech     Hybrid Journal   (Followers: 6)
Current Drug Discovery Technologies     Hybrid Journal   (Followers: 6)
Current Drug Delivery     Hybrid Journal   (Followers: 6)
Current Therapeutic Research     Open Access   (Followers: 6)
Expert Review of Cardiovascular Therapy     Full-text available via subscription   (Followers: 6)
Neuropharmacology     Hybrid Journal   (Followers: 5)
Current Drug Metabolism     Hybrid Journal   (Followers: 5)
Fitoterapia     Hybrid Journal   (Followers: 5)
Expert Review of Molecular Diagnostics     Full-text available via subscription   (Followers: 5)
Expert Review of Anti-infective Therapy     Full-text available via subscription   (Followers: 5)
Anti-Infective Agents     Hybrid Journal   (Followers: 5)
Toxicon     Hybrid Journal   (Followers: 5)
Medicinal Research Reviews     Hybrid Journal   (Followers: 5)
Investigational New Drugs     Hybrid Journal   (Followers: 5)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry     Hybrid Journal   (Followers: 5)
Current Cancer Therapy Reviews     Hybrid Journal   (Followers: 5)
Reviews of Physiology, Biochemistry and Pharmacology     Hybrid Journal   (Followers: 4)
Planta Medica     Hybrid Journal   (Followers: 4)
Current Vascular Pharmacology     Hybrid Journal   (Followers: 4)
Pharmaceutical Medicine     Full-text available via subscription   (Followers: 4)
Journal of Child and Adolescent Psychopharmacology     Hybrid Journal   (Followers: 4)
CNS Drug Reviews     Open Access   (Followers: 4)
Inpharma Weekly     Full-text available via subscription   (Followers: 4)
Journal of Labelled Compounds and Radiopharmaceuticals     Hybrid Journal   (Followers: 4)
Immunopharmacology and Immunotoxicology     Hybrid Journal   (Followers: 4)
International Journal of Pharmaceutical and Healthcare Marketing     Hybrid Journal   (Followers: 4)
Inflammation Research     Hybrid Journal   (Followers: 4)
Cancer Chemotherapy and Pharmacology     Hybrid Journal   (Followers: 4)
International Journal of Neuropsychopharmacology     Open Access   (Followers: 3)
Pharmacology & Therapeutics     Hybrid Journal   (Followers: 3)
Physiology International     Full-text available via subscription   (Followers: 3)
Cardiovascular Therapeutics     Open Access   (Followers: 3)
ASSAY and Drug Development Technologies     Hybrid Journal   (Followers: 3)
Pharmacopsychiatry     Hybrid Journal   (Followers: 3)
Chemotherapy     Full-text available via subscription   (Followers: 3)
Therapeutic Drug Monitoring     Hybrid Journal   (Followers: 3)
Current Drug Therapy     Hybrid Journal   (Followers: 3)
Research in Social and Administrative Pharmacy     Hybrid Journal   (Followers: 3)
PharmacoEconomics & Outcomes News     Full-text available via subscription   (Followers: 3)
Journal of Aerosol Medicine and Pulmonary Drug Delivery     Hybrid Journal   (Followers: 3)
Journal of Ethnopharmacology     Hybrid Journal   (Followers: 3)
Drug Resistance Updates     Hybrid Journal   (Followers: 3)
Journal of Pain Management & Medicine     Open Access   (Followers: 3)
Journal of Infection and Chemotherapy     Hybrid Journal   (Followers: 3)
Journal of Cardiovascular Pharmacology and Therapeutics     Hybrid Journal   (Followers: 3)
Current Pharmacogenomics and Personalized Medicine     Hybrid Journal   (Followers: 3)
Acta Pharmacologica Sinica     Hybrid Journal   (Followers: 3)
Microbial Drug Resistance     Hybrid Journal   (Followers: 3)
Frontiers in Medicinal Chemistry     Hybrid Journal   (Followers: 3)
Human Psychopharmacology Clinical and Experimental     Hybrid Journal   (Followers: 3)
BMC Pharmacology     Open Access   (Followers: 2)
The Brown University Psychopharmacology Update     Hybrid Journal   (Followers: 2)
International Clinical Psychopharmacology     Hybrid Journal   (Followers: 2)
Canadian Journal of Physiology and Pharmacology     Hybrid Journal   (Followers: 2)
Journal of Drug Targeting     Hybrid Journal   (Followers: 2)
Inflammopharmacology     Hybrid Journal   (Followers: 2)
Journal of Inflammation     Open Access   (Followers: 2)
Fundamental & Clinical Pharmacology     Hybrid Journal   (Followers: 2)
Behavioural Pharmacology     Hybrid Journal   (Followers: 2)
Vascular Pharmacology     Hybrid Journal   (Followers: 2)
Pulmonary Pharmacology & Therapeutics     Hybrid Journal   (Followers: 2)
Biomedicine & Pharmacotherapy     Full-text available via subscription   (Followers: 2)
Clinical Neuropharmacology     Hybrid Journal   (Followers: 2)
Drugs in R & D     Full-text available via subscription   (Followers: 2)
International Immunopharmacology     Hybrid Journal   (Followers: 2)
Pharmacology Biochemistry and Behavior     Hybrid Journal   (Followers: 2)
Letters in Drug Design & Discovery     Hybrid Journal   (Followers: 2)
Archiv der Pharmazie     Hybrid Journal   (Followers: 2)
Pharmacological Reviews     Hybrid Journal   (Followers: 2)
Molecular Pharmacology     Hybrid Journal   (Followers: 2)
Journal of Microencapsulation: Microcapsules, Liposomes, Nanoparticles, Microcells, Microspheres     Hybrid Journal   (Followers: 2)
Toxicological & Environmental Chemistry     Hybrid Journal   (Followers: 2)
Particulate Science and Technology: An International Journal     Hybrid Journal   (Followers: 1)
Pharmacological Research     Hybrid Journal   (Followers: 1)
Current Enzyme Inhibition     Hybrid Journal   (Followers: 1)
Journal of Neuroimmune Pharmacology     Hybrid Journal   (Followers: 1)
Current Pharmaceutical Analysis     Hybrid Journal   (Followers: 1)
Current Neuropharmacology     Hybrid Journal   (Followers: 1)
Pharmacogenetics and Genomics     Hybrid Journal   (Followers: 1)
Journal of Texture Studies     Hybrid Journal   (Followers: 1)
Pharmaceutical Biology     Open Access  
Journal of Liposome Research     Hybrid Journal  
Toxin Reviews     Hybrid Journal  
Kaohsiung Journal of Medical Sciences     Open Access  
Redox Report     Open Access  
Pharmacology     Full-text available via subscription  
Pharmaceutical Chemistry Journal     Hybrid Journal  
NeuroMolecular Medicine     Hybrid Journal  
Journal of Ocular Pharmacology and Therapeutics     Hybrid Journal  
Harm Reduction Journal     Open Access  
Current Nanoscience     Hybrid Journal  
Infectious Disorders - Drug Targets     Hybrid Journal  
Current Bioactive Compounds     Hybrid Journal  
Cancer Biotherapy & Radiopharmaceuticals     Hybrid Journal  
Autonomic & Autacoid Pharmacology     Hybrid Journal  

        1 2 3 | Last   [Sort alphabetically]   [Restore default list]

Similar Journals
Journal Cover
Drugs & Therapy Perspectives
Journal Prestige (SJR): 0.115
Number of Followers: 9  
 
  Full-text available via subscription Subscription journal
ISSN (Print) 1172-0360 - ISSN (Online) 1179-1977
Published by Adis Homepage  [21 journals]
  • Nirmatrelvir plus ritonavir in COVID-19: a profile of its use

    • Free pre-print version: Loading...

      Abstract: Abstract Oral nirmatrelvir plus ritonavir (Paxlovid™) is an effective treatment option for coronavirus disease 2019 (COVID-19), the illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nirmatrelvir inhibits the main protease of SARS-CoV-2, with ritonavir acting as a pharmacokinetic booster. In the phase II/III EPIC-HR trial, nirmatrelvir plus ritonavir reduced the risk of progression to severe COVID-19 in symptomatic, unvaccinated, non-hospitalized adults with mild-to-moderate COVID-19 at high risk for progression to severe disease. The incidence of COVID-19-related hospitalization or death through day 28 was significantly lower with nirmatrelvir plus ritonavir than with placebo. The efficacy of nirmatrelvir plus ritonavir has also been demonstrated in the real-world setting. Nirmatrelvir plus ritonavir is generally well tolerated, with most adverse events being of mild or moderate severity.
      PubDate: 2022-12-06
       
  • Disparities in erythropoiesis-stimulating agent use after changes in
           medicare reimbursement and implementation of a risk evaluation and
           mitigation strategy

    • Free pre-print version: Loading...

      Abstract: Introduction The use of erythropoiesis-stimulating agents (ESAs) for treatment of chemotherapy-induced anemia (CIA) has been linked to potential negative health effects. Additionally, research has identified disparities in ESA utilization for CIA treatment. This study examines (1) health disparities in ESA use and (2) whether reimbursement (Medicare National Coverage Determination [NCD]) or regulatory (Risk Evaluation and Mitigation Strategy [REMS]) policies impacted disparities. Methods In a retrospective cohort study (2006–2018) among 1,747,889 patients with cancer in the United States receiving myelosuppressive chemotherapy at age ≥ 65 years, differences in ESA use for CIA were estimated using generalized estimating equation models, adjusting for policy periods, demographic characteristics, and clinical factors extracted from Medicare claims data. Results After controlling for covariates, ESA use was higher among Black, female, and urban patients in all policy periods, but these disparities decreased significantly following the NCD. The gap continued to close through the REMS period. Disparities in ESA use across geographic regions were modest, and ESA use disparities across socioeconomic characteristics (area deprivation index or dual Medicare/Medicaid eligibility) were not observed. Conclusions Being female, Black, or an urban resident was associated with higher ESA use for CIA in older patients with cancer. Both NCD and REMS implementation helped reduce disparities. REMS release was not observed to contribute to racial, sex, and rural–urban disparities in ESA use for CIA.
      PubDate: 2022-12-06
       
  • Correction to: Amantadine extended release capsules (GOCOVRI®) in
           Parkinson’s disease: a profile of its use in the USA

    • Free pre-print version: Loading...

      PubDate: 2022-11-29
       
  • Limit acne damage with lasers and light therapy

    • Free pre-print version: Loading...

      Abstract: Abstract Active acne, especially inflammatory acne, and subsequent hypopigmentation or erythematous scarring causes significant distress, particularly in adolescents. The outcomes of mostly small trials, and expert opinion, highlights lasers and light devices as relatively fast, effective treatment options. Numerous device configurations exist, and any of the ablative options (e.g. the carbon dioxide laser), non-ablative or vascular lasers and light devices may be appropriate, according to the target lesions. Further investigation is needed, with larger trials.
      PubDate: 2022-11-24
       
  • Consider cannabinoids as an individual therapeutic trial in nociplastic
           pain

    • Free pre-print version: Loading...

      Abstract: Abstract Nociplastic pain, which is characterized by widespread chronic pain and a range of central nervous system and other somatic symptoms, is associated with significant emotional distress and disability. Fibromyalgia is the prototypical example of a nociplastic condition. Traditional treatments for chronic pain, especially nociplastic pain, provide mostly modest relief. Medical cannabis and cannabis-based medicines can potentially address this therapeutic gap. Although evidence supporting their use in nociplastic pain is insufficient to endorse general use, they can be regarded as an individual therapeutic trial if established treatments have failed.
      PubDate: 2022-11-22
       
  • The role of professional socialisation in reducing drug-related problems
           during COVID-19: a new insight for future pandemics

    • Free pre-print version: Loading...

      PubDate: 2022-11-18
       
  • Acknowledgement to Referees

    • Free pre-print version: Loading...

      Abstract: Dear Reader Welcome to the final issue of Drugs & Therapy Perspectives for 2022.
      PubDate: 2022-11-18
       
  • Somatrogon in paediatric growth hormone deficiency: a profile of its use
           in the EU

    • Free pre-print version: Loading...

      Abstract: Abstract Somatrogon (NGENLA®), a modified long-acting form of recombinant human growth hormone (rhGH), is a valuable new option for the treatment of paediatric patients aged ≥ 3 years with growth disturbance due to insufficient GH secretion in the EU, and offers the convenience of once-weekly administration. In a phase 3 randomized trial, once-weekly somatrogon was non-inferior to once-daily somatropin (rhGH; standard therapy) in increasing height velocity in paediatric patients with GH deficiency (GHD). Once-weekly somatrogon was associated with a lower treatment burden than once-daily somatropin in another phase 3 randomized trial. Somatrogon is generally well tolerated, with injection site pain being the most frequent treatment-emergent adverse event. Somatrogon is available as a multi-dose prefilled pen for subcutaneous injection.
      PubDate: 2022-11-18
       
  • Management of central neuropathic pain involves many drugs but few have
           proven efficacy

    • Free pre-print version: Loading...

      Abstract: Abstract Central neuropathic pain (CNP) from injury to the central somatosensory pathways can be difficult to treat. Of the treatments generally considered front-line for neuropathic pain, pregabalin is useful for treating spinal cord injury-related CNP and duloxetine for multiple sclerosis-related CNP. There is also weak evidence supporting amitriptyline and gabapentin use for CNP. A number of other treatment approaches show some promise in a small number of studies but require further investigation.
      PubDate: 2022-11-18
       
  • Monkeypox may be managed with smallpox vaccines and antivirals

    • Free pre-print version: Loading...

      Abstract: Abstract The spread of monkeypox disease (MPX) caused by the zoonotic monkeypox orthopoxvirus (OPXV) has spurred the development of treatment guidelines including pre- and post-exposure prophylaxis with stockpiled vaccines against OPXVs, particularly smallpox vaccines. Pre-exposure prophylaxis is recommended for occupationally exposed and high-risk populations, including those with HIV. Active therapies based on preclinical models include antivirals, such as tecovirimat, brincidofovir and cidofovir; vaccinia immune globulin may also be considered.
      PubDate: 2022-11-18
       
  • mRNA COVID-19 vaccines are well tolerated and myopericarditis is a rare
           adverse event following immunisation

    • Free pre-print version: Loading...

      Abstract: Abstract mRNA vaccines are considered to be important tools for the management of the COVID-19 pandemic. Although mRNA COVID-19 vaccines are well tolerated in most recipients, post-marketing data have highlighted an association between myocarditis and mRNA vaccines. Post-vaccine myocarditis (PVM) is most commonly reported in male adolescents receiving the second dose of an mRNA vaccine. However, the incidence of PVM is low and the risk of myocarditis should be kept in perspective. Cases of PVM are mostly mild in severity, and may be managed using existing myocarditis guidelines. The pathology of PVM is under investigation, and current data suggest that cross reactivity or hypersensitivity reactions may be involved. Globally, mRNA vaccines are generally recommended for use in children/adolescents, and delaying the administration of the second dose may reduce the risk of PVM.
      PubDate: 2022-11-15
       
  • Many drugs are available for hypertension, with more in development

    • Free pre-print version: Loading...

      Abstract: Abstract Hypertension is a global health issue that is associated with an increased risk for poor cardiovascular outcomes and kidney failure. A wide range of antihypertensive drugs are currently available for the pharmacological management of hypertension, such as drugs that target the renin‑angiotensin‑aldosterone system, calcium channel blockers, adrenergic drugs and diuretics. Guidelines by the International Society of Hypertension outlines a four-step treatment pathway, and recommends that treatments be tailored to patients’ needs. Newer drugs are now available for the management of hypertension, and other drugs are currently in later stages of development.
      PubDate: 2022-11-15
       
  • Mitotane in adrenocortical carcinoma: a profile of its use

    • Free pre-print version: Loading...

      Abstract: Abstract The adrenal cytotoxic agent mitotane (Lysodren®) has a central role in the systemic treatment of adrenocortical carcinoma (ACC), a rare and aggressive cancer of the adrenal glands. Although its precise mechanism of action remains unclear, mitotane has been evaluated and used for more than 60 years and, to date, is the only drug specifically approved for the treatment of ACC. Although ACC continues to be associated with a poor prognosis, mitotane has been shown to provide clinically significant benefit in a good proportion of ACC patients treated with the drug, both in the advanced (unresectable/metastatic) disease and adjuvant therapy settings. While mitotane has generally manageable tolerability with most adverse events (including neurotoxicity) being reversible with dose reduction or treatment interruption, regular monitoring of drug plasma concentrations during treatment is important to help ensure optimal use of mitotane while minimising the impact of drug toxicity.
      PubDate: 2022-11-11
       
  • Correction: Difelikefalin in pruritus associated with chronic kidney
           disease: a profile of its use

    • Free pre-print version: Loading...

      PubDate: 2022-11-09
       
  • Opioid misuse in older patients requires careful consideration of many
           factors

    • Free pre-print version: Loading...

      Abstract: Abstract There is insufficient clinical data on how to optimally treat and manage opioid misuse in older patients. Opioid use affects older adults differently to younger patients, which significantly impacts management strategies and treatment outcomes. Every older patient should be regularly screened for opioid use disorder. Detoxify, then manage withdrawal, utilising mainly buprenorphine and methadone, but consider physiological differences in older patients as well as comorbidities and concomitant medications.
      PubDate: 2022-11-09
       
  • Approach the prevention of chemotherapy-induced nausea and vomiting in
           older patients with care

    • Free pre-print version: Loading...

      Abstract: Abstract Chemotherapy-induced nausea and vomiting (CINV) negatively affects adherence to treatment and quality of life in older patients, and should be managed differently due to physiological and/or psychological changes; also consider impacts of patient comorbidities and polypharmacy. Prevent CINV using serotonin 3-receptor antagonists, neurokinin 1-receptor antagonists, corticosteroids and other drug classes (dopamine 2,3-receptor antagonists should mainly be used as a rescue antiemetic), and simplify CINV prophylaxis as much as possible. Further data is needed for CINV prophylaxis in older patients for optimal guideline-directed treatment.
      PubDate: 2022-11-05
       
  • Association between polypharmacy, patient-reported symptoms, and quality
           of life among nonalcoholic fatty liver disease patients in the United
           States

    • Free pre-print version: Loading...

      Abstract: Background Nonalcoholic fatty liver disease (NAFLD) is a silent disease, yet patients might report nonspecific symptoms. The objectives of this study were to examine the effect of polypharmacy on patient-reported symptoms in NAFLD adult patients and to examine the impact of patient-reported symptoms on quality of life (QoL). Methods A retrospective observational study was conducted to evaluate NAFLD patient-reported symptoms, QoL, and polypharmacy in the US. QoL was measured using the 36-Item Short Form Survey (SF-36) questionnaire. Patients were classified as having polypharmacy if they used five medications or more. The comparisons of patient-reported symptoms between patients with and without polypharmacy were done using the Wilcoxon Rank Sum Test. To examine each symptom and its effect on QoL, multivariable linear models were performed on QoL scores. Results The study included 1032 patients. The average percentage of reporting “none at all” in patients with polypharmacy was 50%, while it was 66% in the non-polypharmacy group (p < 0.01). In multivariable linear models, the symptoms that had a negative impact on QoL in terms of physical health were muscle weakness, fatigue, and swelling of ankles (B = − 13.7, − 9.7, and − 7.914, respectively; all p < 0.01). For mental health, depression/sadness, fatigue, and muscle weakness were the most common symptoms that negatively affected QoL (B = − 20.3, − 11.2 and − 7.1, respectively; all p < 0.01) Conclusion NAFLD patients with polypharmacy reported more symptoms than NAFLD patients with non-polypharmacy. Fatigue and muscle weakness were the most common symptoms that negatively affected physical health QoL, while depression/sadness and fatigue had a negative impact on mental health QoL.
      PubDate: 2022-11-03
       
  • First reports of adverse drug reactions

    • Free pre-print version: Loading...

      PubDate: 2022-11-02
       
  • Correction to: Prevalence and predictors of inappropriate apixaban dosing
           in patients with non‑valvular atrial fibrillation at a large tertiary
           academic medical institution

    • Free pre-print version: Loading...

      PubDate: 2022-10-31
       
  • First reports of adverse drug reactions and drug interactions

    • Free pre-print version: Loading...

      PubDate: 2022-10-18
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 3.239.112.140
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-